| 2022 | | A novel biguanide (IM1761065) inhibits bioenergetics of glioblastoma tumorspheres | 노태훈 |
| 2004 | | Analysis of prognostic factors in the patients with glioblastoma | 강성원, 김세혁, 안영환, 윤수한, 조경기, 조기홍 |
| 2020 | | Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy | 노태훈 |
| 2010 | | Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions. | 김상현, 조경기 |
| 2023 | | Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study) | 김세혁 |
| 2019 | | Epigenetic downregulation of STAT6 increases HIF-1alpha expression via mTOR/S6K/S6, leading to enhanced hypoxic viability of glioma cells | 김세혁, 김현미, 박수정, 조은혜, 주일로 |
| 2011 | | Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells. | 김세혁 |
| 2022 | | Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open-label phase 2 study | 김세혁 |
| 2017 | | Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis | 노태훈 |
| 2018 | | Multiple systemic extraneural metastasis of glioblastoma | 노태훈 |
| 2012 | | Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases | 김보영, 김세혁, 김영배, 김장희, 신승수, 이기범, 이현우, 정선용, 한재호 |
| 2018 | | Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation | 김세혁 |
| 2015 | | Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance. | 김세혁, 우현구 |
| 1997 | | The Effect of All-trans and 13-cis-retinoic Acid in Medulloblastoma and Glioblastoma Cell Culture | 김성환, 김세혁, 안영환, 윤수한, 조경기, 조기홍 |
| 2020 | | Treatment Results for Recurrent Glioblastoma and Alteration of Programmed Death-Ligand 1 Expression After Recurrence | 노태훈 |
| 2020 | | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial | 김세혁 |
| 2017 | | Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma | 김세혁, 우현구 |
